CEBPA mutations in AML: site matters

Tools

Preview

PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
693kB

Item Type:	Editorial
Title:	CEBPA mutations in AML: site matters
Creators Name:	Bullinger, L.
Abstract:	In this issue of Blood, based on a retrospective analysis of 4708 acute myeloid leukemia (AML) cases, Taube et al evaluate the impact of CCAAT/enhancer binding protein a (CEBPA) mutations and show that it is especially in-frame mutations affecting the basic leucine zipper region (bZIP) of CEPBA that confer a favorable outcome, irrespective of their occurrence as biallelic (CEBPAbi) or single mutation (CEBPAsm). Compared with transactivation domain (TAD) mutations, this study strongly supports a previously undefined role of CEBPA bZIP mutations, which is reflected in a distinct disease biology including younger age, higher white blood cell counts, the presence of GATA2 mutations, and high complete remission rates and long median event-free and overall survival.
Keywords:	Acute Myeloid Leukemia, CCAAT-Enhancer-Binding Proteins, Mutation
Source:	Blood
ISSN:	0006-4971
Publisher:	American Society of Hematology
Volume:	139
Number:	1
Page Range:	6-7
Date:	6 January 2022
Additional Information:	Copyright © 2022 by The American Society of Hematology
Official Publication:	https://doi.org/10.1182/blood.2021013557
PubMed:	View item in PubMed

Repository Staff Only: item control page

Download Statistics

Downloads

Downloads per month over past year